The interaction between acetylation and serine-574 phosphorylation regulates the apoptotic function of FOXO3.
The multispecific transcription factor and tumor suppressor FOXO3 is an important mediator of apoptosis, but the mechanisms that control its proapoptotic function are poorly understood. There has long been evidence that acetylation promotes FOXO3-driven apoptosis and recently a specific JNK (c-Jun N-terminal kinase)-dependent S574 phosphorylated form (p-FOXO3) has been shown to be specifically apoptotic. This study examined whether acetylation and S574 phosphorylation act independently or in concert to regulate the apoptotic function of FOXO3. We observed that both sirtuins 1 and 7 (SIRT1 and SIRT7) are able to deacetylate FOXO3 in vitro and in vivo, and that lipopolysaccharide (LPS) treatment of THP-1 monocytes induced a rapid increase of FOXO3 acetylation, partly by suppression of SIRT1 and SIRT7. Acetylation was required for S574 phosphorylation and cellular apoptosis. Deacetylation of FOXO3 by SIRT activation or SIRT1 or SIRT7 overexpression prevented its S574 phosphorylation and blocked apoptosis in response to LPS. We also found that acetylated FOXO3 preferentially bound JNK1, and a mutant FOXO3 lacking four known acetylation sites (K242, 259, 290 and 569R) abolished JNK1 binding and failed to induce apoptosis. This interplay of acetylation and phosphorylation also regulated cell death in primary human peripheral blood monocytes (PBMs). PBMs isolated from alcoholic hepatitis patients had high expression of SIRT1 and SIRT7 and failed to induce p-FOXO3 and apoptosis in response to LPS. PBMs from healthy controls had lower SIRT1 and SIRT7 and readily formed p-FOXO3 and underwent apoptosis when similarly treated. These results reveal that acetylation is permissive for generation of the apoptotic form of FOXO3 and the activity of SIRT1 and particularly SIRT7 regulate this process in vivo, allowing control of monocyte apoptosis in response to LPS.
Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
Z
Z
Li
Liver Center, University of Kansas Medical Center, Kansas City, KS, USA.
B
B
Bridges
Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
J
J
Olson
Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.|Liver Center, University of Kansas Medical Center, Kansas City, KS, USA.
S A
SA
Weinman
D000107:Acetylation; D000328:Adult; D017209:Apoptosis; D002460:Cell Line; D005260:Female; D000071316:Forkhead Box Protein O3 / Q000378:metabolism*; D006519:Hepatitis, Alcoholic / Q000276:immunology / Q000378:metabolism; D006801:Humans; D008070:Lipopolysaccharides / Q000276:immunology; D008297:Male; D008875:Middle Aged; D048055:Mitogen-Activated Protein Kinase 8 / Q000378:metabolism; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D009000:Monocytes / Q000276:immunology / Q000378:metabolism; D010766:Phosphorylation; D011485:Protein Binding; D059748:Proteolysis; D012694:Serine / Q000378:metabolism*; D015398:Signal Transduction; D037761:Sirtuins / Q000378:metabolism
D000071316:Forkhead Box Protein O3; D008070:Lipopolysaccharides; D012694:Serine; D048055:Mitogen-Activated Protein Kinase 8; D020928:Mitogen-Activated Protein Kinases; D037761:Sirtuins
PLoS One. 2009 Dec 22;4(12):e8414
20027304
J Cell Sci. 2010 Dec 15;123(Pt 24):4251-8
21081649
Mol Cell Biol. 2000 Dec;20(24):9138-48
11094066
N Engl J Med. 2009 Jun 25;360(26):2758-69
19553649
Oncogene. 2008 Apr 7;27(16):2276-88
18391970
Aging Cell. 2007 Aug;6(4):505-14
17521387
Science. 2004 Mar 26;303(5666):2011-5
14976264
Cell. 2006 Nov 3;127(3):635-48
17081983
PLoS One. 2008;3(12):e4020
19107194
Diabetologia. 2011 May;54(5):1136-46
21340626
Breast Cancer Res. 2008;10 (1):R21
18312651
Am J Pathol. 2013 Dec;183(6):1815-25
24095927
Cell Stem Cell. 2007 Jun 7;1(1):101-12
18371339
Science. 2002 Apr 19;296(5567):530-4
11964479
Oncogene. 2008 Apr 7;27(16):2312-9
18391973
EMBO Mol Med. 2013 Mar;5(3):430-40
23364955
Exp Mol Med. 2007 Feb 28;39(1):8-13
17334224
Hepatology. 2009 Apr;49(4):1326-34
19133650
Cell Metab. 2013 Sep 3;18(3):416-30
24011076
Cell. 2001 Oct 19;107(2):149-59
11672523
J Biol Chem. 2001 Oct 19;276(42):38837-43
11483616
J Cell Sci. 2012 Mar 1;125(Pt 5):1191-203
22349704
Carcinogenesis. 2013 Jul;34(7):1476-86
23514751
Genome Biol. 2004;5(5):224
15128440
J Biol Chem. 2010 Oct 29;285(44):33959-70
20817729
FASEB J. 2010 Sep;24(9):3145-59
20385619
Free Radic Biol Med. 2013 Oct;63:222-34
23665396
Biochem Biophys Res Commun. 2008 Apr 11;368(3):690-5
18249187
Nature. 2009 Apr 23;458(7241):1056-60
19262508
J Biol Chem. 2011 Aug 26;286(34):29681-90
21705328
Cancer Res. 2011 Nov 1;71(21):6878-87
21911455
Inflammation. 2007 Apr;30(1-2):1-6
17115116
Nat Cell Biol. 2008 Feb;10 (2):138-48
18204439
Cell Death Differ. 2016 Apr;23 (4):583-95
26470730
Lancet. 1983 Dec 24-31;2(8365-66):1492
6140576
Cell Stress Chaperones. 2015 Sep;20(5):805-10
25981116
Front Pharmacol. 2012 Feb 28;3:29
22403547
Oncogene. 2012 Mar 22;31(12 ):1546-57
21841822
J Biol Chem. 2011 Jun 24;286(25):22227-34
21540183
Biochem Biophys Res Commun. 2009 Apr 10;381(3):372-7
19236849
Nat Rev Immunol. 2007 Mar;7(3):202-12
17318231